Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSunpharmaceuticalindustries

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy IndusInd Bank, Hindustan Unilever, Sun Pharmaceutical Industries: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying IndusInd Bank, Hindustan Unilever and Sun Pharmaceutical Industries.

    • Hold Sun Pharma, says Sharmila Joshi

      According to Sharmila Joshi of sharmilajoshi.com, one may hold Sun Pharma.

    • Remain invested in Sun Pharma: Rajat Bose

      Rajat Bose of rajatkbose.com is of the view that one may remain invested in Sun Pharmaceutical Industries.

    • Wondering which stock will outperform in Q1? Morgan Stanley lists out 4 stocks which could double PAT

      Morgan Stanley said Tata Motors and Tata Steel should be the biggest positive contributors to Sensex earnings.

    • Resistance for Nifty at 9816; buy L&T, Bosch, Eicher, Sun Pharma: Prakash Gaba

      According to Prakash Gaba of prakashgaba.com, crucial support for the Nifty is at 9675 and the resistance is at 9816. He has four bullish calls including Bosch, Eicher Motors, L&T and Sun Pharma.

    • Sun Pharma, Zee Entertainment looks good: Prakash Gaba

      Prakash Gaba of prakashgaba.com is of the view that Sun Pharma looks good for target of Rs 580 and Zee Entertainment for target of Rs 520.

    • Buy Sun Pharmaceutical Industries, Tata Consultancy Services: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Sun Pharmaceutical Industries and Tata Consultancy Services.

    • Here are some fundamental trading ideas from SP Tulsian

      In an interview to CNBC-TV18, SP Tulsian of sptulsian.com shared his readings and outlook on market and specific stocks.

    • Buy Sun Pharma, Lupin, Asian Paints, Yes Bank, Balrampur Chini, BASF: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying Sun Pharma, Lupin, Asian Paints, Yes Bank, Balrampur Chini and BASF.

    • Sell Indiabulls Real Estate, Suven Life Sciences: Sandeep Wagle

      Sandeep Wagle of powermywealth.com recommends selling Indiabulls Real Estate and Suven Life Sciences.

    • Aurobindo, Cipla, Biocon top picks; see FDA plan to be double edged sword: Citi

      In the last nine months to one year time, the pharma stock prices were plummeted by 20-35 percent.

    • Prefer Dr Reddy's, Sun Pharmaceutical: Hemant Thukral

      Hemant Thukral of Aditya Birla Money is of the view that one may prefer Dr Roddy’s Laboratories and Sun Pharmaceutical.

    • Nifty may remain volatile ahead of expiry; 4 stocks to pick today: Prakash Gaba

      Prakash Gaba of prakashgaba.com is of the view that crucial support for the Nifty is at 9520-9466 and the resistance is at 9620-9700-9724 and has Mindtree and Sun Pharma as bullish plays while he has Tech Mahindra and UPL as bearish plays.

    • Buy Asian Paints, M&M, Sun Pharma, Kotak Mahindra Bank, Dabur, HUDCO: VK Sharma

      VK Sharma, Head of Business, Private Client Group at HDFC Securities recommends buying Asian Paints, Mahindra and Mahindra, Sun Pharmaceutical Industries, Kotak Mahindra Bank, Dabur India and HUDCO.

    • Buy Bharat Forge, Colgate, Federal Bank; sell Sun Pharma: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com advises buying Bharat Forge, Colgate Palmolive, Federal Bank and India Cements.

    • Conviction Buys! Top 22 stocks where fund managers hold more than 2% in portfolio

      Some quality names in IT and pharma are available at appealing valuations which are attracting smart money into these stocks.

    • Ujjivan Financial Services may test Rs 320-325: Hemant Thukral

      Hemant Thukral of Aditya Birla Money feels that Ujjivan Financial Services may test Rs 320-325.

    • Keep two years' view on RIL to make good money out of it: Deven Choksey

      In an interview to CNBC-TV18, Deven Choksey, MD of KR Choksey Investment Managers shared his views on public sector banks, Reliance Industries Ltd (RIL), IT and pharma.

    • Stay invested in Sun Pharma: Sharmila Joshi

      Sharmila Joshi of sharmilajoshi.com is of the view that one may stay invested in Sun Pharmaceutical Industries.

    • Reduce call on Sun Pharma, target price lowered to Rs 501: Prabhudas Lilladher

      Sun Pharmaceutical Industries has received a United States Foods and Drug Administration (US-FDA) approval for cholesterol drug Zetia generic that Glenmark Pharma had exclusivity on which they had received all the way back in December but that is not the only story for Sun. this is the second approval that they have received just in the past week from US-FDA.

    • Avoid Delta Corp, says Sudarshan Sukhani

      According to Sudarshan Sukhani of s2analytics.com, one may avoid Delta Corp.

    • Sun Pharma & Tech Mahindra: Should you be catching these falling knives?

      Latest quarterly numbers from Sun Pharma and Tech Mahindra have come as a shocker for investors. Both companies belong to sectors experiencing pain and in the midst of a major overhaul.

    • Buy Motherson Sumi, HDFC; sell Reliance Power: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com is of the view that one can buy Motherson Sumi and HDFC and sell Reliance Power, Reliance Infra and Reliance Capital.

    • Buy Vedanta, Tata Steel: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com suggests buying Vedanta and Tata Steel.

    • HDFC Securities positive on Divis, Cadila; neutral on Sun Pharma

      In an interview to CNBC-TV18, Amey Chalke, Research Analyst at HDFC Securities shared his readings and outlook on a few of the pharma stocks.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347